1. What Happened?

SD Biotech is facing delisting from the KOSDAQ. The final decision will be made after an appeal period following the KOSDAQ Market Committee’s vote.

2. Why is this Happening?

SD Biotech recorded a net loss in Q1 2025, highlighting its deteriorating financial condition. High debt ratio, intensifying competition, and sluggish performance in new business areas outside of their core mask pack products are cited as key factors. External factors such as rising interest rates and increasing raw material prices have exacerbated the company’s struggles.

3. What Happens Next?

Two scenarios are possible depending on the outcome of the appeal. If successful, SD Biotech may retain its listing, but without fundamental improvements to its financials, its difficulties may persist. If the appeal fails, delisting will be confirmed, likely leading to a sharp drop in share price and significant losses for investors. The company may face corporate restructuring or acquisition.

4. What Should Investors Do?

  • Stay Informed: Continuously monitor the company’s disclosures, news, and analyst reports for the latest information.
  • Careful Investment Decisions: Consider the outcome of the appeal and the future business outlook comprehensively before making any investment decisions.
  • Consult with Experts: If necessary, consult with investment professionals to develop an appropriate investment strategy.